Navigation Links
Potential new treatment for gastrointestinal cancers discovered
Date:1/17/2013

Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential to be developed into a new treatment for these diseases.

The complex of proteins, known as mTorc1 (mammalian target of rapamycin complex 1), has previously been implicated in the development of some other cancers but this is the first time it has been shown to promote the growth of colon and gastric cancers that are associated with inflammation.

Dr Stefan Thiem and Associate Professor Matthias Ernst from the Walter and Eliza Hall Institute's Cell Signalling and Cell Death division made the discovery with colleagues while at the Melbourne-Parkville Branch of the Ludwig Institute for Cancer Research. Associate Professor Ernst is a Ludwig Institute Member. Their findings are published online today in the Journal of Clinical Investigation.

Cancers of the digestive system are a significant cause of death in Australia. Colon (or bowel) cancer causes more than 4000 deaths annually more than any other cancer except lung cancer while more than 1000 Australians die from gastric (or stomach) cancer each year.

Ernst said many types of colon and gastric cancer were associated with chronic inflammation. "We have previously shown that the immune system's inflammatory response can promote the growth of tumours," he said. "In the digestive system, persistent inflammatory conditions have been linked with tumour growth: patients who have stomach ulcers or gastritis (inflammation of the stomach lining) are more susceptible to gastric cancer, while inflammation of the colon, called colitis, is associated with an increased risk of developing colon cancer."

The research team found that inflammation-associated gastric and colon cancers showed activation of mTorc1, an aggregate of proteins that signals inside cells to promote growth. Many cancer types depend on mTorc1 activity to grow, and there is considerable interest in the use of mTorc1 inhibitors to treat cancer.

The growth of inflammation-associated colon and gastric cancers could be treated with mTorc1 inhibitors, Ernst said. "We were excited to discover that the growth of these cancers in laboratory models could be prevented by treatment with mTorc1 inhibitors that are already in clinical trials for other types of cancer," he said. "In the future, we hope that this finding might lead to better treatment options for colon and gastric cancers that are associated with inflammation. Since there are also other types of cancer that are associated with inflammation, we suspect that these could also be susceptible to treatment with mTorc1 inhibitors."


'/>"/>

Contact: Vanessa Solomon
solomon@wehi.edu.au
61-393-452-971
Walter and Eliza Hall Institute

Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research


Source:Eurekalert  

Related medicine news :

1. Da Vinci Surgery Robot Lawsuit Website Launched by Bernstein Leibhard LLP to Inform Public about Potential Da Vinci Surgery Complications
2. Impending Mandate on Event Data Recorders Raises Concern amongst Auto Manufactures - Kiley Law Group Weighs in on Potential to Save Lives
3. High-throughput sequencing shows potentially hundreds of gene mutations related to autism
4. Honda Issues Recall of 800K Vehicles, Philadelphia Attorneys at Console & Hollawell Warn Consumers of Their Potential Risks
5. Robotic-assisted radical bladder surgery potentially benefits bladder cancer patients
6. UAlberta medical researchers discover new potential chemotherapy
7. New screening approach identified potential drug combos for difficult-to-treat melanomas
8. Frog-in-bucket-of-milk folklore leads to potential new antibiotics
9. ‘A Subtle Addiction – Attacking the Y Generation’ - New Book by Peter & Lynn McIntosh Begs the Question "Is an Ipad, Kindle or Smart Phone a Safe Gift or a Potential Radiation Cancer Risk this Holiday Season?"
10. Potential gene therapy approach to sickle cell disease highlighted at American Society of Hematology
11. Targeted prostate biopsy has potential to improve diagnosis of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential new treatment for gastrointestinal cancers discovered
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology: